Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees and Multiple Sites

summarizeSummary

Galapagos NV announced its Board of Directors has decided to initiate the wind-down of its cell therapy activities, following a strategic review and completion of works council consultations. This decision will impact approximately 365 employees and result in the closure of several sites.

check_boxKey Events

• Strategic Wind-Down Initiated

  Galapagos' Board of Directors has decided to initiate the wind-down of its cell therapy activities after completing works council consultations.

• Significant Operational Impact

  The wind-down will affect approximately 365 employees and lead to the closure of sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai.

• Repositioning for Future Growth

  The company will reposition for long-term growth through transformational business development, maintaining non-cell therapy activities like the GLPG3667 program.

• Strong Cash Position

  As of December 31, 2025, Galapagos held approximately €3.0 billion in cash and cash equivalents.

auto_awesomeAnalysis

This decision marks a significant strategic pivot for Galapagos, indicating a failure to achieve desired outcomes in its cell therapy division. While the immediate impact is negative due to job losses and site closures, the company aims to reposition for long-term growth through new business development and focus on its non-cell therapy pipeline, such as the TYK2 program GLPG3667. Investors should monitor the upcoming financial guidance for estimated wind-down costs and the company's progress in identifying new transformational opportunities.